Table 1.
Demographics and comorbidity status of patients with rheumatoid arthritis who were new or continuing etanercept or adalimumab therapy
| New patients N = 1,023 | Continuing patients N = 1,089 | |||
|---|---|---|---|---|
| ETN n = 572 | ADA n = 451 | ETN n = 688 | ADA n = 401 | |
| Age group (years), n (%) | ||||
| 18–25 | 12 (2.1) | 6 (1.3) | 11 (1.6) | 2 (0.5) |
| 26–35 | 44 (7.7) | 28 (6.2) | 25 (3.6) | 16 (4.0) |
| 36–45 | 106 (18.5) | 84 (18.6) | 85 (12.4) | 59 (14.7) |
| 46–55 | 210 (36.7) | 169 (37.5) | 256 (37.2) | 119 (29.7) |
| 56–64 | 200 (35.0) | 164 (36.4) | 311 (45.2) | 205 (51.1) |
| Sex, n (%) | ||||
| Female | 461 (80.6) | 366 (81.2) | 546 (79.4) | 310 (77.3) |
| Male | 110 (19.2) | 83 (18.4) | 142 (20.6) | 91 (22.7) |
| Missing | 1 (0.2) | 2 (0.4) | 0 | 0 |
| Region, n (%) | ||||
| Northeast | 64 (11.2) | 70 (15.5) | 96 (14.0) | 68 (17.0) |
| Midwest | 144 (25.2) | 116 (25.7) | 154 (22.4) | 106 (26.4) |
| South | 192 (33.6) | 169 (37.5) | 232 (33.7) | 140 (34.9) |
| West | 172 (30.1) | 95 (21.1) | 206 (29.9) | 87 (21.7) |
| Missing | 0 | 1 (0.2) | 0 | 0 |
| Quan-Charlson index, mean score [SD] | 1.4 [0.7] | 1.5 [0.9] | 1.3 [0.8] | 1.3 [0.7] |
| Received methotrexate in pre-index period, n (%) | 361 (63.1) | 298 (66.1) | 344 (50.0) | 234 (58.4) |
ADA adalimumab, ETN etanercept, SD standard deviation